These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 35476295)

  • 1. Targeting IDH-Mutant Glioma.
    Miller JJ
    Neurotherapeutics; 2022 Oct; 19(6):1724-1732. PubMed ID: 35476295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapies for IDH-Mutant Gliomas.
    Alshiekh Nasany R; de la Fuente MI
    Curr Neurol Neurosci Rep; 2023 May; 23(5):225-233. PubMed ID: 37060388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas.
    Wakimoto H; Tanaka S; Curry WT; Loebel F; Zhao D; Tateishi K; Chen J; Klofas LK; Lelic N; Kim JC; Dias-Santagata D; Ellisen LW; Borger DR; Fendt SM; Vander Heiden MG; Batchelor TT; Iafrate AJ; Cahill DP; Chi AS
    Clin Cancer Res; 2014 Jun; 20(11):2898-909. PubMed ID: 24714777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics of IDH-mutant gliomas with non-canonical IDH mutation.
    Poetsch L; Bronnimann C; Loiseau H; Frénel JS; Siegfried A; Seizeur R; Gauchotte G; Cappellen D; Carpentier C; Figarella-Branger D; Eimer S; Meyronet D; Ducray F;
    J Neurooncol; 2021 Jan; 151(2):279-286. PubMed ID: 33205355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gray Areas in the Gray Matter:
    van den Bent MJ; Mellinghoff IK; Bindra RS
    Am Soc Clin Oncol Educ Book; 2020 Mar; 40():1-8. PubMed ID: 32186930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isocitrate dehydrogenase mutation as a therapeutic target in gliomas.
    Han CH; Batchelor TT
    Chin Clin Oncol; 2017 Jun; 6(3):33. PubMed ID: 28705010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine.
    Turcan S; Fabius AW; Borodovsky A; Pedraza A; Brennan C; Huse J; Viale A; Riggins GJ; Chan TA
    Oncotarget; 2013 Oct; 4(10):1729-36. PubMed ID: 24077826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas.
    Appay R; Dehais C; Maurage CA; Alentorn A; Carpentier C; Colin C; Ducray F; Escande F; Idbaih A; Kamoun A; Marie Y; Mokhtari K; Tabouret E; Trabelsi N; Uro-Coste E; Delattre JY; Figarella-Branger D;
    Neuro Oncol; 2019 Dec; 21(12):1519-1528. PubMed ID: 31832685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implications of IDH mutations on immunotherapeutic strategies for malignant glioma.
    Richardson LG; Miller JJ; Kitagawa Y; Wakimoto H; Choi BD; Curry WT
    Neurosurg Focus; 2022 Feb; 52(2):E6. PubMed ID: 35104795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular biology and novel therapeutics for IDH mutant gliomas: The new era of IDH inhibitors.
    Kitagawa Y; Kobayashi A; Cahill DP; Wakimoto H; Tanaka S
    Biochim Biophys Acta Rev Cancer; 2024 May; 1879(3):189102. PubMed ID: 38653436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impending Impact of Molecular Pathology on Classifying Adult Diffuse Gliomas.
    Macaulay RJ
    Cancer Control; 2015 Apr; 22(2):200-5. PubMed ID: 26068765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perspectives of immunotherapy in isocitrate dehydrogenase-mutant gliomas.
    Friedrich M; Bunse L; Wick W; Platten M
    Curr Opin Oncol; 2018 Nov; 30(6):368-374. PubMed ID: 30102604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IDH1-Mutation in Diffuse Gliomas in Persons Age 55 Years and Over.
    Robinson C; Kleinschmidt-DeMasters BK
    J Neuropathol Exp Neurol; 2017 Feb; 76(2):151-154. PubMed ID: 28110298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a Good-Prognosis IDH-Mutant-Like Population of Patients with Diffuse Gliomas.
    Wang Z; Liu X; Wang Z; Bao Z; Zhang W; Zhang C; Jiang T
    Curr Mol Med; 2018 Mar; 17(7):518-526. PubMed ID: 29437008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The presence of TIM-3 positive cells in WHO grade III and IV astrocytic gliomas correlates with isocitrate dehydrogenase mutation status.
    Sørensen MD; Nielsen O; Reifenberger G; Kristensen BW
    Brain Pathol; 2021 May; 31(3):e12921. PubMed ID: 33244787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in the Immunotherapeutic Potential of Isocitrate Dehydrogenase Mutations in Glioma.
    Tang F; Pan Z; Wang Y; Lan T; Wang M; Li F; Quan W; Liu Z; Wang Z; Li Z
    Neurosci Bull; 2022 Sep; 38(9):1069-1084. PubMed ID: 35670952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular Pathogenesis of Low-Grade Glioma.
    Bready D; Placantonakis DG
    Neurosurg Clin N Am; 2019 Jan; 30(1):17-25. PubMed ID: 30470401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accelerated progression of IDH mutant glioma after first recurrence.
    Miller JJ; Loebel F; Juratli TA; Tummala SS; Williams EA; Batchelor TT; Arrillaga-Romany I; Cahill DP
    Neuro Oncol; 2019 May; 21(5):669-677. PubMed ID: 30668823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Noninvasive assessment of isocitrate dehydrogenase mutation status in cerebral gliomas by magnetic resonance spectroscopy in a clinical setting.
    Tietze A; Choi C; Mickey B; Maher EA; Parm Ulhøi B; Sangill R; Lassen-Ramshad Y; Lukacova S; Østergaard L; von Oettingen G
    J Neurosurg; 2018 Feb; 128(2):391-398. PubMed ID: 28298040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multi-institutional study of the frequency, genomic landscape, and outcome of IDH-mutant glioma in pediatrics.
    Yeo KK; Alexandrescu S; Cotter JA; Vogelzang J; Bhave V; Li MM; Ji J; Benhamida JK; Rosenblum MK; Bale TA; Bouvier N; Kaneva K; Rosenberg T; Lim-Fat MJ; Ghosh H; Martinez M; Aguilera D; Smith A; Goldman S; Diamond EL; Gavrilovic I; MacDonald TJ; Wood MD; Nazemi KJ; Truong A; Cluster A; Ligon KL; Cole K; Bi WL; Margol AS; Karajannis MA; Wright KD
    Neuro Oncol; 2023 Jan; 25(1):199-210. PubMed ID: 35604410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.